Biohaven Shares Fall 12% After FDA Halts New Enrollment in Epilepsy Drug Trial

Biohaven Pharmaceutical (NYSE: BHVN) shares fell 12.0% in pre-market trading on September 10 after the company disclosed that U.S. regulators paused new patient enrollment in trials for its lead epilepsy drug candidate, BHV-7000.

FDA Imposes Partial Clinical Hold

The U.S. Food and Drug Administration (FDA) placed a partial clinical hold on the BHV-7000 epilepsy program, effective September 4, 2026. According to the company, the hold requires additional nonclinical studies to be completed before any new participants can be dosed. The agency's request stems from a metabolite that was detected during rodent research.

The hold is partial in nature, meaning the more than 600 patients already randomized across the trials will continue to receive treatment. Biohaven also noted that its fully enrolled pivotal study, BHV7000-303, remains on track to report topline data in the second half of the year.

Ad

Market Reaction and Investor Concerns

The regulatory action triggered a significant sell-off, pulling the stock toward $13.20 in pre-open activity. For a clinical-stage company like Biohaven, its valuation is heavily dependent on the successful and timely progression of its pipeline assets. The enrollment freeze introduces meaningful uncertainty regarding the drug's development timeline and ultimate regulatory path.

Adding to investor unease, Biohaven filed a Form 8-K with the Securities and Exchange Commission (SEC) on the same day, a formal disclosure of a material event whose full details have not yet been widely disseminated. The stock's decline was specific to the company, as the broader S&P 500 was trading flat, indicating the pressure was not related to a wider market or sector downturn.